Global Lysosomal Enzymes Market, By Drugs (Velaglucerase, Imiglucerase, Alglucosidase, Others), Indication (Gaucher Disease, Mucopolysaccharidosis, Pompe Disease, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029
Lysosomal Enzymes Market Analysis and Size
The global lysosomal enzymes market is expected to witness significant growth during the forecast period. Rising prevalence of rare disorders worldwide and emerging markets are the factors responsible for the growth of this market. The growth of lysosomal enzymes market enhanced by the growing cases of lysosomal disease and increased research and development activities. In addition, advances in the treatment options and the presence of well-established healthcare facilities are some of the impacting factors for the growth of eosinophil driven diseases market. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global lysosomal enzymes market in the forecast period 2022-2029. The expected CAGR of global lysosomal enzymes market is tend to be around 7% in the mentioned forecast period. The market was valued at USD 7.4 billion in 2021, and it would grow upto USD 12.71 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Lysosomal disease or simply lysosomal storage diseases are a rare inherited metabolic disorder. It is caused by defective or mutant metabolism which leads to absence or deficiency of enzymes that result in inappropriate build-up of material in various body cells. Lysosomal enzymes are the medicines that act as enzyme replacement therapy and are widely used in treating lysosomal storage diseases.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drugs (Velaglucerase, Imiglucerase, Alglucosidase, Others), Indication (Gaucher Disease, Mucopolysaccharidosis, Pompe Disease, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Bristol-Myers Squibb Company (U.S.), AstraZeneca(U.K.), Sun Pharmaceutical Industries Limited (India), Sanofi (France), Arena Pharmaceuticals, Inc. (California), Raptor Pharmaceuticals Inc. (U.S.), ltragenyx Pharmaceutical (U.S.), Sino Biological, Inc (China), Polaryx therapeutics (U.S.)
|
|
Market Opportunities
|
|
Global Lysosomal Enzymes Market Dynamics
Drivers
- Increase in Elderly Population
According to the WHO, elderly people aged 60 years and above is expected to rise from 900 million in 2015 to 2 billion in 2050. This will lead to surge in incidence of different lysosome related diseases. This boosts the market growth.
- Rise in Fabry Disease
As per the reports from the National Institutes of Health Genetics Home Reference, the prevalence of fabry disease is around 1 in 40,000 to 60,000 males globally. As per the rcords of the National Center for Biotechnology Information (NCBI), the prevalence of Fabry disease in white male populations was 1:17,000 to 1:117,000 in the U.S in January 2020.
Opportunities
- Increased Clinical Research and Activities
There was huge increase in R&D in the field of artificial genetic material. Various therapeutic approaches such as enzyme replacement therapy and development of synthetic enzymes contributed to the development in the treatment of lysosomal storage disorder. This is another factor expected to drive growth of the lysosomal enzymes market.
- Increasing Demand for Retail Pharmacies
The rise in the number of drugs for eosinophil driven diseases delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Impending Drug Approvals
There are many drugs or injections that await for the approval of the drugs. Receiving approval for the drug from regulatory authorities is a very tedious and challenging task as regulatory authorities such as the U.S. FDA execute substantial and burdensome requirements upon companies involved in the clinical development, marketing, manufacturing, and distribution of drugs
- High Cost
The huge expenditure associated with these agents surely hamper the market growth.
This global lysosomal enzymes market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global lysosomal enzymes market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Lysosomal Enzymes Market
Considering the present scenario, COVID-19 has left an unprecedented global public health crisis that has impacted practically every business. Its long-term repercussions are expected to influence industry growth during the forecast period. Transition of healthcare infrastructure toward managing COVID-19 has led to drug launch cancellations and delays in clinical trials. A number of research activities have been performed to understand the relation between the COVID-19 and lysosomal enzyme driven diseases. Additionally, research has been ongoing in which researchers are trying to understand the correlation of mortality in patients due to the COVID-19 and lysosomal disorders.
In the post-pandemic era, the biotechnology and pharmaceutical industries are expected to witness a huge growth in the future, due to the demand for vaccine and treatment drugs for COVID-19. Thus, this will significantly impact the global lysosomal enzymes market.
Global Lysosomal Enzymes Market Scope
The global lysosomal enzymes market is segmented on the basis of drug, indication, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drugs
- Velaglucerase
- Imiglucerase
- Alglucosidase
- Others
Indication
- Gaucher Disease
- Mucopolysaccharidosis
- Pompe Disease
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Lysosomal Enzymes Market Regional Analysis/Insights
The global lysosomal enzymes market is analysed and market size insights and trends are provided by drug, indication, distribution channel and end-user as referenced above.
The major countries covered in the global lysosomal enzymes market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for global lysosomal enzymes market throughout the forecasted period due to the global leaders in research and development activities and vulnerable lysosomal storage disease population.
Asia-Pacific dominates the market due to the developing healthcare facilities, large number of generic manufacturer and rise in government initiatives and specialist communities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Lysosomal Enzymes Market Share Analysis
The global lysosomal enzymes market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global lysosomal enzymes market.
Key players operating in the global lysosomal enzymes market include:
- Bristol-Myers Squibb Company (U.S.)
- AstraZeneca(U.K.)
- Sun Pharmaceutical Industries Limited(India)
- Sanofi ( France)
- Arena Pharmaceuticals, Inc.( California)
- Raptor Pharmaceuticals Inc. (U.S.)
- ltragenyx Pharmaceutical (U.S.)
- Sino Biological, Inc (China)
- Polaryx® therapeutics (U.S.)
SKU-